Overview

A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation

Status:
NOT_YET_RECRUITING

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical trial is to evaluate the efficacy and safety of camrelizumab plus apatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after radical resection or ablation.

Phase:

PHASE2

Details

Lead Sponsor:

Zhujiang Hospital

Treatments:

apatinib
camrelizumab